Physician profile
Julio E Arronte
NPI 1699793042
$1,723.15
in general payments reported to CMS, 2019-2025
20 companies · $613 in 2025
The $613 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $38.48 · 2021: $272 · 2022: $205 · 2023: $254 · 2024: $136 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,003.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,003.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $473.63 | 2019-2023 | Rinvoq, Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $296.04 | 2023-2025 | Veozah |
| Coloplast Corp | $240.93 | 2025 | |
| Coopersurgical, INC. | $227.66 | 2019-2025 | Ally II Ups, Paragard T 380a, Paragard T 380a |
| Hologic Sales and Service, LLC | $81.53 | 2024-2025 | Aptima, Thinprep 2000 Processor |
| Biogen, INC. | $57.99 | 2025 | Zurzuvae |
| Channel Medsystems, INC. | $56.09 | 2023 | |
| Evofem Biosciences, INC. | $42.22 | 2022-2024 | |
| Daiichi Sankyo INC. | $41.48 | 2019-2021 | |
| Pfizer INC. | $39.29 | 2019-2024 | |
| Genzyme Corporation | $37.29 | 2020-2021 | |
| Medicem INC. | $31.22 | 2022 | |
| Optumhealth Care Solutions, LLC | $22.54 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
| Myovant Sciences INC. | $21.67 | 2021 | |
| Organon LLC | $21.18 | 2025 | Nexplanon |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.40 | 2020 | |
| Mission Pharmacal Company | $13.99 | 2019 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julio Arronte listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.